GL-ONC1 Clinical Results
GL-ONC1 has been evaluated in four completed Phase 1/1b human clinical trials with 89 cancer patients. GL-ONC1 was tested against a wide range of cancer types, with various methods of administration (i.e. intravenously or regionally), either as a single agent therapy or in combination with conventional therapy. There are three (3) important readouts: importantly, these readouts are transferable across different sites, primary investigators, protocols and cancer types!
(i) Safety. GL-ONC1 is well-tolerated, without significant adverse side effects, without concerns about environmental spread, and without reaching a “Maximum Tolerated Dose”.
(ii) Mechanism of Action. Through clinically-preferred routes of administration, the virus has been delivered successfully to the tumor, infected and selectively killed tumor cells – such as those that establish deadly new metastases, and initiated an anti-tumoral immune response.
(iii) Clinical Benefit. Although the completed Phase 1/1b studies were designed primarily for safety, GL-ONC1 has been shown to have encouraging evidence of efficacy, with anti-tumor activities including tumor reduction/durable stabilization of disease and other documented clinical benefits for patients.